Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer
Status:
Recruiting
Trial end date:
2024-10-05
Target enrollment:
Participant gender:
Summary
For locally advanced gastric cancer (cT3-4aN+M0), neoadjuvant chemotherapy can downstage T
and N stage, increase the resectability of tumor, and finally improve the long-term survival.
Combination of perioperative PD-1 antibody and chemotherapy for locally advanced gastric
cancer could be a novel therapy to increase response rate and resectability and reduce
recurrence rate. JS001 in this study is a Chinese anti-PD-1 monoclonal antibody for injection
which has been approved for melanoma. This study is a multi-center, open-label, randomized
phase II clinical trial to evaluate tolerability, safety and efficacy of JS001 in combination
with perioperative chemotherapy in locally advanced gastric cancer.